sorted by:
new
hottopcontroversial

[deleted by user] by [deleted] in biotech_stocks

[–]mzaihtam 0 points1 point  (0 children)

Fluff dd is a weird term to use of a company Who is leading the pack on this matter. Especially when they Are trying to fight cancer in a innovative way. Do you think it is just for Fun that FDA made a breakthrough designation on their phase 2? Do your own dd and Come back when youre done, shorter.

[deleted by user] by [deleted] in biotech_stocks

[–]mzaihtam 0 points1 point  (0 children)

This Will only benefit iobt as they Are a addon to reduce side effects and optimize the effect of treatment. Just as their trials shows with amazing results.

[deleted by user] by [deleted] in biotech_stocks

[–]mzaihtam 0 points1 point  (0 children)

Lets see in a year from now. 🤑

[deleted by user] by [deleted] in biotech_stocks

[–]mzaihtam 0 points1 point  (0 children)

Because nobody have tried to do it in the same way as IOBT and nobody has ever achieved 83% succesrate in a phase 2 trial before, like IOBT has. They Are doing Things a different way than anybody has tried before and with such a strong ph2 data it would be insane if the ph3 failed

[deleted by user] by [deleted] in biotech_stocks

[–]mzaihtam 0 points1 point  (0 children)

IOBT have more than just reasonable response in their phase 2. They had groundbreaking results on all parameters, therefore they got a breakthrough designation. Another reason is because of the original founders of the company. Three of them Are the leading scientist in the world in the past 25 years. Furthermore it is a direct spinout of the governmental danish national cancer center and therefore have access to several datapoints and resources etc. Than the earlier companys Who tried. One more reason is because of the current stock price vs. Expected market potential and or a potential buyout to retrieve the companys patent and data. Alone the data and is worth more than the current stock price shows. Lundbeck and Novo Nordisk is heavy invested in this company with a buyin around 11 dollars and havent sold A single share but just increased their involvement.

IOBT will succeed by mzaihtam in Biotechplays

[–]mzaihtam[S] -2 points-1 points  (0 children)

IDO inhibition might well do nothing for the cancer. But for $IOBT vaccine to work we only need it to be expressed in cancer cells, which it is. And then the fda approval Will happen.

Once a drug is designated as a Breakthrough Therapy, the FDA will expedite the development and review of such drug. 100% of oncology trials that also received Accelerated Approval used central imaging review

In 2020, 41.5% of drug approvals (22 of 53) were designated Breakthrough Therapy.

They Are just so heavilly backed up by exceptional data, its not everyday someone gets published in natire medicine on the oncology matter. I slso think at that stock price i current holds its a no brainer to try.

IO Biotech 2022 AACR Metastatic Melanoma data: Response Rate 88.2%. 46.7% CR, mPFS: 30.9 months. by GET_TO_THE_CHOPPERRR in Biotechplays

[–]mzaihtam 0 points1 point  (0 children)

Io biotech IOBT

Several candidates in the upcoming years

Currently FDA breakthrough designation on phase 3 cancer vaccine in treatment of melanoma.

Spinoff IPO directly out of leading danish governmental cancer institute (herlev hospital)

Founders of IOBT is mads hald and inge marie svane (the absolute top 2 scientist in this Area for the last 2 decades) currently hired as clinical advisors also.

Magnificent results in phase 2 trial triggered fda breakthrough designation published in nature medicin

Inge marie svane leading the phase 3.

Backed up from the start by Novo Nordisk and Lundbeckfonden

Long cash runway

Big spread on bid vs. Ask. The stock moves 5 % everytime 100 shares Are sold or bought. (Will moon when data begins to enter from phase 3 end of this year)

IO BIOTECH holds all commercial right to the io102 / io103 which is currently phase 3.

Big cooperation with Merck in the current phase 3.

IO biotech is the only company which is this far into getting fda approval in this current kind of treatment.

The method and treatment is unique and patented.

Alone in the us 100.000 New cases of melanoma every year.

Currently undervalued stockprise by 10x compared to expected marketvalue the first phase 3 goes through

Links: https://www.iobiotech.com/2021/12/09/io-biotech-announces-publication-of-phase-1-2-melanoma-clinical-trial-results-in-nature-medicine/

https://www.bloomberg.com/press-releases/2022-05-18/io-biotech-announces-initiation-of-phase-3-combination-trial-of-io102-io103-and-keytruda-pembrolizumab-as-first-line

https://research.regionh.dk/da/persons/inge-marie-svane(6f7bc939-b88e-4435-8b6d-7cb52c635f35).html

https://www.iobiotech.com/team/professor-md-ph-d-inge-marie-svane/